| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.21 | 0.2 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.2 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |